DSC
OBIO icon

Daytona Street Capital’s Orchestra BioMed OBIO Stock Holding History

Daytona Street Capital’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Buy
96,398
+43,798
+83% +$179K 0.28% 80
2026
Q1 		$235K Buy
52,600
+31,100
+145% +$132K 0.18% 113
2025
Q4 		$89.2K Buy
+21,500
New +$86.7K 0.07% 188

Other funds holding OBIO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
MFP
Meramec Financial Planners Saint Louis, Missouri $274M AUM
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Daytona Street Capital's OBIO Position: Q2 2026 in Review

Daytona Street Capital increased its Orchestra BioMed (OBIO) stake by 83% in Q2 2026, buying an estimated $179K and bringing the position to 96,398 shares worth $379K. The position accounts for 0.28% of the portfolio, ranked #80.

Daytona Street Capital first reported a position in OBIO in Q4 2025 and has held it in 3 quarters since. 21 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Daytona Street Capital held 96,398 shares of Orchestra BioMed worth $379K as of Q2 2026.
  • Daytona Street Capital bought 43,798 Orchestra BioMed shares in Q2 2026, an estimated $179K.
  • Orchestra BioMed made up 0.28% of Daytona Street Capital's portfolio in Q2 2026, its #80 holding.
  • Daytona Street Capital first reported a position in Orchestra BioMed in Q4 2025 and has held it in 3 quarters since.
  • 21 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Daytona Street Capital's 13F filing for Q2 2026, filed 3 Aug 2026.